Research Analysts Issue Forecasts for CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at William Blair dropped their Q2 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, May 20th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($2.27) per share for the quarter, down from their prior estimate of ($1.10). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.16) EPS, FY2025 earnings at ($6.17) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($3.25) EPS.

Other research analysts have also issued research reports about the company. Barclays lowered their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Friday, May 9th. Truist Financial upped their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Stifel Nicolaus lowered their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Finally, JMP Securities reiterated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Stock Up 3.3%

Shares of NASDAQ CRSP traded up $1.20 during midday trading on Thursday, reaching $38.06. The company had a trading volume of 876,829 shares, compared to its average volume of 1,688,043. The firm's fifty day moving average price is $36.95 and its 200-day moving average price is $41.77. The stock has a market cap of $3.29 billion, a PE ratio of -8.70 and a beta of 1.88. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same period in the prior year, the business posted ($1.43) earnings per share. The business's revenue was up 71.6% on a year-over-year basis.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. SVB Wealth LLC purchased a new position in shares of CRISPR Therapeutics during the first quarter valued at about $25,000. Wood Tarver Financial Group LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $30,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the first quarter valued at about $27,000. Ameriflex Group Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $36,000. Finally, Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This trade represents a 5.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,021 shares of company stock valued at $594,771 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.